Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.59 |
| ▸ | MGAM | O43451 | 6/20 | 0.59 |
| ▸ | SI | P14410 | 3/20 | 0.59 |
| ▸ | GBA1 | P04062 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | LCT | P09848 | 1/20 | 0.59 |
| ▸ | GBA2 | Q9HCG7 | 8/20 | 0.53 |
| ▸ | UGCG | Q16739 | 3/20 | 0.53 |
| ▸ | AGL | P35573 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9426822 | 1.00 | GAA (0.59) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL466824 | 1.00 | GAA (0.59) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL2265507 | 0.82 | GAA (0.66) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL18709118 | 0.81 | GAA (0.59) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL17128703 | 0.79 | GAA (0.66) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL26679472 | 0.78 | GAA (0.70) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL2270637 | 0.78 | GAA (0.70) | GAAMGAMSIGBA1TDP1 | |
| Methane SCHEMBL9426826 | 0.77 | GAA (0.36) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL2274019 | 0.76 | GAA (0.68) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL23996577 | 0.76 | GAA (0.49) | GAAMGAMSIGBA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5411970-A | Method of inhibiting lentivirus | G. D. SEARLE & CO. (US) | 1995-05-02 | — | — | US | claimed |
| EP-0445098-A2 | Deoxynojirimycin derivatives as antiviral agents | G.D. SEARLE & COMPANY (US) | 1991-09-04 | — | — | EP | claimed |
| US-4957926-A | ALKYLIMINO-DIDEOXY-GLUCITOL COMPOUND | MONSANTO COMPANY (US) | 1990-09-18 | — | — | US | claimed |
| EP-2023927-B1 | DEOXYNOJIRIMYCIN AND D-ARABINITOL ANALOGS AND METHODS OF USING | UNITED THERAPEUTICS CORP (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8097728-B2 | Iminosugar compounds with antiflavirus activity | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-7612093-B2 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITED THERAPEUTICS CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-12 | — | — | US | disclosed |
| EP-1658846-B1 | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections | UNITED THERAPEUTICS CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1061922-B9 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | UNITED THERAPEUTICS CORPORATION | 2006-11-23 | — | — | US | disclosed |
| EP-1714676-A2 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. Searle LLC. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1030839-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999024401-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5151519-A | PROCESS FOR THE PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G. D. SEARLE & CO. (US) | 1992-09-29 | — | — | US | disclosed |
| US-5151519-A | PROCESS FOR THE PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G. D. SEARLE & CO. (US) | 1992-09-29 | — | — | US | disclosed |
| WO-1991017145-A1 | PROCESS FOR PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
| WO-1991017145-A1 | PROCESS FOR PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
| WO-1991017145-A1 | PROCESS FOR PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | IMPDH1, HAVCR2, DERA | GAA 429/4885MGAM 60/4885SI 151/4885 |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | INSRR, RNASEL, AGL | GAA 1145/4885MGAM 73/4885SI 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.